Association Française de Promotion de la Recherche Médicale/ French Association for the Medical Research Advancement
Page d'accueilActions engageesProjets Collaboratifs internationauxBibliographie_Therapie_Insitu

References _ Imdendrim

1-World Cancer Report 2014 [43 583 KB]

2-Michael J Hughes and Ewen M Harrison. Malignant liver tumours. Hepatobiliary Surgery, 2014, 32 (12) : 655-660 [136 KB]

3-El Serag H. Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterology 2012; 142: 1264-73 [874 KB] .

4- Norton JA. Surgical treatment of neuroendocrine metastases. BestPract Res Clin Gastroenterol 2005;19(4):577–83. [218 KB]

5. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-yearsurvival after resection of colorectal liver metastases defines cure. JClinOncol 2007;25(29):4575–8 [108 KB] 0.

6- Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol 2002;29(2):107–18 [112 KB] .

7. Lutz MP, Wilke H, Wagener DJ, et al. Weekly infusional highdosefluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/ FA), or HD-FU/FA plus biweekly cisplatin in advanced gastriccancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer GastrointestinalGroup and the Arbeitsgemeinschaft Internistische Onkologie. JClinOncol 2007;25(18):2580–5. [115 KB]

8 Albert M, Kiefer MV, Sun W, et al. Chemoembolization ofcolorectal liver metastases with cisplatin, doxorubicin, mitomycinC, ethiodol, and polyvinyl alcohol. Cancer 2011;117(2):343–52. [183 KB]

9. Dong XD, Carr BI. Hepatic artery chemoembolization for thetreatment of liver metastases from neuroendocrinetumors: a longtermfollow-up in 123 patients. Med Oncol 2011;28(1_suppl.):286–90. [163 KB]

10. Martin R, Joshi J, Robbins K, et al. Hepatic Intra-ArterialInjection of Drug-Eluting Bead, Irinotecan (DEBIRI) in unresectablecolorectal liver metastases refractory to systemic chemotherapy:results of multi-institutional study. Ann SurgOncol 2011;18(1): 192–8 [188 KB] .

11. Siena S, Peeters M, Van Cutsem E, et al. Association ofprogression-free survival with patient-reported outcomes andsurvival: results from a randomised phase 3 trial of panitumumab.Br J Cancer 2007;97(11):1469–74. [176 KB]

12. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequencyablation of neuroendocrine liver metastases. World J Surg 2002;26(8):985–90. [47 KB]

13. Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C. Percutaneous radiofrequency ablation of hepatic colorectal metastases:technique, indications, results, and new promises. Invest Radiol 2004;39(11):689–97. [94 KB]

14. Van Cutsem E. Integration of the anti-EGFR agent panitumumabinto clinical practice in metastatic colorectal cancer. Clin AdvHematolOncol 2007;5(8):611–3. [343 KB]

15 Forner A, Llovet J, Bruix J. Chemoebolization for intermiediate HCC: isthere proof of survival benefit? J Hepatol 2012; 56: 984e6. [233 KB]

16. Salem R, Thurston KG. Radioembolization with 90yttriummicrospheres: a state-of-the-art brachytherapy treatment forprimary and secondary liver malignancies: Part 1: technical and methodologic considerations. J VascIntervRadiol 2006;17(8):1251–78. [1 881 KB]

17. Salem R, Thurston KG. Radioembolization with 90yttriummicrospheres: a state-of-the-art brachytherapy treatment forprimary and secondary liver malignancies: Part 2: special topics.JVascIntervRadiol 2006;17(9):1425–39. [307 KB]

18. Salem R, Thurston KG. Radioembolization with yttrium-90microspheres: a state-of-the-art brachytherapy treatment forprimary and secondary liver malignancies: part 3: comprehensiveliterature review and future direction. J VascIntervRadiol 2006;17(10):1571–93. [257 KB]

19. Breedis C, Young G. The blood supply of neoplasms in the liver.Am J Pathol 1954;30(5):969–77 [3 797 KB] .

20. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolizationfor hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes. Gastroenterology2010;138(1):52–64. [370 KB]

21. Salem R, Lewandowski RJ, Atassi B, et al. Treatment ofunresectable hepatocellular carcinoma with use of 90Y microspheres(TheraSphere): safety, tumor response, and survival. JVasc Interv Radiol 2005;16(12):1627–39. [881 KB]

22. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90resin microsphere radioembolization of hepatocellular carcinomaacross Barcelona clinic liver cancer stages: a European evaluation.Hepatology 2011;54(3):868–78. [277 KB]

23. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization withyttrium-90 glass microspheres in hepatocellular carcinoma: Europeanexperience on safety and long-term survival. Hepatology2010;52(5):1741–9. [337 KB]

24. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolizationof colorectal hepatic metastases using yttrium-90 microspheres.Cancer 2009;115(9):1849–58. [218 KB]

25. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolizationfor neuroendocrine liver metastases: safety, imaging, andlong-term outcomes. Int J RadiatOncolBiol Phys 2012;83(3):887–94. [69 KB]

26. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microspherebrachytherapy for unresectable colorectal liver metastases:modern USA experience. Int J RadiatOncolBiol Phys 2006;65(2):412–25. [1 105 KB]

27. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trialcomparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver limited metastatic colorectal cancerrefractory to standard chemotherapy.J ClinOncol 2010;28(23):3687–94. [234 KB]

28. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolizationfor unresectable neuroendocrine hepatic metastases using resin90Y-microspheres: early results in 148 patients. Am J ClinOncol2008;31(3):271–9. [200 KB]

29 Salem R et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres : a comprehensive report of long-term outcomes. Gastroenteroly. 2010 ; 138(1) : 52-64 [370 KB]

30. A.B. Benson III, Jean-Francois Geschwind b, Mary F. Mulcahy et al. Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study / European Journal of Cancer 49 (2013) 3122–3130, [257 KB]

31, Adams G. Hypoxia-mediated drugs for radiation and chemotherapy. Cancer, 1981 ; 48 ; 696-707 [1 130 KB]

32. Brizel DM et al. Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996; 56: 941-943 [702 KB]

33, Seddon BM et al. The role of functional and molecular imaging in cancer drug discovery and development. Brit J Radial. 2003; 76: S128- S138). [139 KB]

34. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000;92(3):205–16. [529 KB]

35. Belhadj-Tahar H, Faye C, Regnier T, Garrely L, Coulais Y (2012) Etudes de Toxicocinétique et de biodistribution de dendrimères de cinquième génération.Proceedings of 8èmes Journées Cancéropôle Grand Sud-Ouest. [1 995 KB]

36. B. Romestand et Coll. (2010) Dendrigraft Poly-L-lysine: A Non-Immunogenic Synthetic Carrier for Antibody Production Biomacromolecules , 11: 1169–1173 [236 KB]

37 Belhadj-Tahar H, Yang G, Sadeg G (2017) Acute toxicology and biodistribution preclinical studies of new 188-Rhenium and 99m-Technetium bearingnitro- Imidazolic probe (NGT1) Proceedings of 8èmes JournéesCancéropôle Grand Sud-Ouest. [3 071 KB]

38 Belhadj-Tahar H, Coulais Y, Nassar B (2013) Acute Toxicity Test And Biodistribution After Intravenous And Intraperitonial Administration In The Rat « Dendrimere G5{1-Nitro-1h-Imidazole-Methyl-1,2,3-Triazol-Methyl-Di-(2-Pycolyl)Amine} (2013). Toxicological Report “ref AFPreMed DendrimA_HBYC2013”. [3 071 KB]

39. Yang G, Sadeg N, Belhadj-Tahar H (2016) Preclinical studies of new In situ therapeutic agent derived from dendrimer combined with Nitro-Imidazole rhenium-188 complex. Proceedings of XIIemes journées de Cancéropôle Grand Sud-Ouest. [1 470 KB]

40 Yang G, Sadeg N, Belhadj-TaharH (2017) New Potential In Situ Anticancer Agent Derived from [188Re]rhenium Nitro-Imidazole Ligand Loaded 5th Generation Poly-L-Lysine Dendrimer for Treatment of Transplanted Human Liver Carcinoma in Nude Mice. Drug Des 2017, 6 (1):1-7. [3 112 KB]

41. Belhadj-Tahar H, Sadeg N, Yang G. Intra-Tumoral Hepatic Administration Under CT Stereotactic and Ultrasound Guidance of in Situ Anti-Cancer Agent Derived from [188re]Rhenium Nitro-Imidazole Ligand Loaded 5th Generation Poly-l-Lysine Dendrimer. International Journal of Radiation Oncology Biology Physics, 2019; 105: 1, Supplement, Page E642 [61 KB]

42. Belhadj-Tahar H, Chen J, Song P, Zhao J, Quan M, Caixin Li, Gu X, Sadeg N, Yang G, Gao Y. New Anticancer agent derived from [188Re] Rhenium-Nitro Imidazole Complex Loaded 5th Generation Poly-L-lysine Dendrimer for Computed Tomography-Guided Lung Malignancies In situ treatment. World J Nucl Med. 2019 Jul-Sep; 18(3): 324–344.

Version imprimable